Cite

HARVARD Citation

    Bae, J. et al. (2016). Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutation. Diagnostic pathology. 11 (1), pp. 1-10. [Online]. 
  
Back to record